Akari Therapeutics PLC · NASDAQ:AKTX
Farag Kameel D. received 2,873 Akari Therapeutics PLC shares as an award (Form 4)
Traded Nov 17, 2026 · Filed Nov 19, 2026
On Nov 17, 2026, Farag Kameel D. (Interim CFO) received 2,873 Akari Therapeutics PLC shares as an award at an average US$9.05 for US$25,992, leaving 26,182 shares. Filed Nov 19, 2026 (Form 4).
- Awarded
- 2,873 shares
- Price
- US$9.05 average (US$8.18 to US$10.12)
- Value
- US$25,992
- Holding after
- 26,182 shares
- Trading plan
- No
- Role
- Interim CFO
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Nov 17, 2026 | American Depositary Shares representing Ordinary Shares | Award | 1,284 | US$10.12 | 24,593 | Direct |
| Nov 17, 2026 | American Depositary Shares representing Ordinary Shares | Award | 1,589 | US$8.18 | 26,182 | Direct |
Source
Download original · View original at SEC
Related
- Akari Therapeutics PLC
- Farag Kameel D.
- Akari Therapeutics PLC shareholders
- Schedule 13G/A · MMCAP International Inc. SPC · Nov 13, 2026
- Schedule 13G/A · Bank Of Montreal · Nov 12, 2026
- Form 4 · Patel Sandip I · Oct 16, 2026
- Form 4 · Bazemore Robert B · Oct 16, 2026
- Form 4 · Gaslightwala Abizer · Oct 16, 2026